NCT03715725View on ClinicalTrials.gov

A Nationwide Observational Study Looking at Effectiveness and Bleeding Complications of NOACs vs. VKA in Non-valvular Atrial Fibrillation Patients.

TerminatedOBSERVATIONAL
Enrollment

70,000

Participants

Timeline

Start Date

October 31, 2018

Primary Completion Date

January 20, 2020

Study Completion Date

January 20, 2020

Conditions
Non-valvular Atrial Fibrillation
Interventions
DRUG

Rivaroxaban (Xarelto, BAY59-7939)

Administration according to clinical practice

DRUG

Apixaban (Eliquis)

Administration according to clinical practice

DRUG

Dabigatran etexilate (Pradaxa)

Administration according to clinical practice

DRUG

Warfarin (Marevan)

Administration according to clinical practice

Trial Locations (1)

Unknown

Many Locations, Multiple Locations

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
collaborator

Janssen Research & Development, LLC

INDUSTRY

lead

Bayer

INDUSTRY